CD25
Ongoing clinical trials and approved products targeting CD25, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.
2ongoing therapy trials
0ongoing imaging trials
0approved products
Target note
- Full name
- CD25 (interleukin-2 receptor α chain)
- Nature
- Membrane receptor of activated and regulatory T lymphocytes.
- Normal expression
- Activated T cells and Tregs.
- Disease expression
- Hodgkin lymphoma, T-cell lymphomas, hairy cell leukemia.
- Value
- Irradiating tumor cells and the lymphoid microenvironment, notably as intensification before autologous transplant.
- Approaches
- Basiliximab antibody labeled with ⁹⁰Y.
- Indications explored
- Relapsed Hodgkin and T-cell lymphomas, with BEAM conditioning.
- Points of caution
- Myelotoxicity; data limited to phases 1-2.
| Trial | Phase | Status | Sponsor | Countries |
|---|
| [90Y]BasiliximabNCT04871607 · Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 1 |
| [90Y]Basiliximab (anti-CD25)NCT05139004 · Leukemia / transplant conditioning | Phase 1 | Active, not recruiting | City of Hope Medical Center | 1 |
Cite this page
CD25. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/cd25/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.